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Background: “Probable active syphilis,” is deﬁned as seroreactivity in both non-treponemal and treponemal tests.
A correction factor of 65%, namely the proportion of pregnant women reactive in one syphilis test type that were
likely reactive in the second, was applied to reported syphilis seropositivity data reported toWHO for global es-
timates of syphilis during pregnancy. Objectives: To identify more accurate correction factors based on test type
reported. Search Strategy:Medline search using: “Syphilis [Mesh] and Pregnancy [Mesh],” “Syphilis [Mesh] and
Prenatal Diagnosis [Mesh],” and “Syphilis [Mesh] and Antenatal [Keyword]. Selection Criteria: Eligible studies
must have reported results for pregnant or puerperal women for both non-treponemal and treponemal serology.
Data collection and analysis:Wemanually calculated the crude percent estimates of subjects with both reactive
treponemal and reactive non-treponemal tests among subjects with reactive treponemal and among subjects
with reactive non-treponemal tests. We summarized the percent estimates using random effects models.
Main results: Countries reporting both reactive non-treponemal and reactive treponemal testing required no cor-
rection factor. Countries reporting non-treponemal testing or treponemal testing alone required a correction fac-
tor of 52.2% and 53.6%, respectively. Countries not reporting test type required a correction factor of 68.6%.
Conclusions: Future estimates should adjust reported maternal syphilis seropositivity by test type to ensure
accuracy.
© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
In 2088,WHO estimated that, worldwide, approximately 1.4 million
pregnant women had “probable active syphilis” (PAS) or syphilis infec-
tions sufﬁciently active to result in mother-to-child transmission
(MTCT) and with the potential of subsequent adverse pregnancy out-
comes [1]. Syphilis in pregnancy can be devastating and is associated
with poor fetal or infant outcomes in themajority of cases, with an esti-
mated 52% of PAS cases resulting in an adverse perinatal outcome
attributable to syphilis [2]. PAS (deﬁned as seroreactivity for both
non-treponemal and treponemal tests) is used as the reportingmeasure
by WHO since surveillance data typically do not include clinical
information.
Currently, no single test or combination of tests accurately predicts
the extent to which maternal syphilis infection in pregnancy will affect
the fetus. However, serologic tests can be suggestive; the combination
of a reactive non-treponemal test (e.g. rapid plasma regain [RPR],and Prevention, 1600 Clifton Rd
behalf of International Federation ofvenereal disease research laboratory [VDRL]) and a reactive treponemal
test (e.g. Treponema pallidum particle agglutination [TP-PA], T. pallidum
hemagglutination assay), deﬁned in the 2008WHO estimates as PAS, is
compelling evidence for an infection that may result in MTCT. Neither
type of test is both sensitive and speciﬁc on its own. A reactive, but
unconﬁrmed, non-treponemal test may represent a biological false-
positive result, whereas a reactive treponemal test alonemay represent
an old or previously treated infection that poses little exposure risk for
the fetus. Considered schematically (Table 1), individuals with a posi-
tive result in both test types are likely to have syphilis (Cell A). Those
with a single positive result in either test type could have syphilis, but
might have false-positive or past-treated infection (Cells B and C).
Those with negative results in both test types are unlikely to have syph-
ilis (Cell D).
WHO estimated that untreated syphilis in pregnancy resulted in
approximately 521 000 adverse perinatal outcomes globally in
2008, including an estimated 212 000 stillbirths, 92 000 neonatal
deaths, 65 000 preterm or low birth weight infants, and 152 000
syphilis-infected newborns [1]. Health outcomes were modeled based
on the published literature on MTCT risk of syphilis transmission [2] and
national data reported to WHO from 147 countries on antenatal clinic
(ANC) attendance (at least one visit) and from 97 countries on maternalGynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
Table 1
Schematic of syphilis testing by test type.
Treponemal test
Reactive Non-reactive
Non-treponemal
test
Reactive A (syphilis likely) B (biologic false positive)
Non-reactive C (possible past infection) D (syphilis unlikely)
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Global AIDS Response Progress Reporting System (GARPR, formerly
known as HIV Universal Access Reporting: http://www.unaids.org/en/
dataanalysis/knowyourresponse/globalaidsprogressreporting/). Mater-
nal syphilis seropositivity data reported to WHO varied across coun-
tries, generally falling into four categories (Table 2). Category 1
included countries reporting the number of maternal syphilis cases
reactive to both non-treponemal and treponemal syphilis tests (PAS);
Category 2 included countries reporting cases reactive to non-
treponemal syphilis tests only (i.e. no conﬁrmatory treponemal testing
reported); Category 3 included countries reporting cases reactive to
treponemal tests only (i.e. no conﬁrmatory non-treponemal testing
reported); and Category 4 included countries for which the type of
laboratory test used was not reported.
In the 2008 estimates on burden of syphilis in pregnancy, WHO ap-
plied a correction factor assuming that 65% of all reported seropositive
cases among pregnant women, regardless of test type, had infections
that could lead to MTCT (PAS). A correction factor was necessary since
97% (188 of 193) of countries reporting to WHO had not reported on
the test type used (Category 4), and many may have included only
one test type (treponemal or non-treponemal) in their case deﬁnition.
The correction factor was based on data from three ANC studies in
which both non-treponemal and treponemal test results were reported
[3–5], allowing calculation of the proportion of seropositive women in
either test type expected to be reactive for both non-treponemal and
treponemal tests (i.e. A/(A + B + C), Table 1). This estimation is best
suited for Category 4 countries. However, for countries in Categories
1− 3,more precise correction factors can be calculated. In this analysis,
we sought to identify more accurate correction factors for future esti-
mates of global burden of syphilisMTCT and resultant adverse pregnan-
cy outcomes when test type data are available. Correction factors
calculated were the estimated proportion of pregnant or puerperal
women with reactive non-treponemal tests that had reactive trepone-
mal tests (correction factor for Category 2 countries), or the proportion
of pregnant or puerperal women with reactive treponemal tests
that had reactive non-treponemal tests (correction factor for Category 3
countries).Table 2
Syphilis seropositivity in antenatal women: WHO reporting categories based on syphilis test ty
Syphilis seropositivity
WHO reporting categories Category 1
(countries reporting based on
both reactive non-treponemal
and reactive treponemal testing)
Category 2
(countries reporting ba
non-treponemal testing
Previous correction factor used
for estimating probable active
syphilis WHO [1]
65% 65%
Assumptions used for new
correction factors
Additional correction factor not
needed; reported data represent
best estimate of probable active
syphilis when only test type
data are available
Proportion of pregnan
with reactive non-trep
that also have reactive
tests; A/(A + B) from
New correction factor estimate
(95% CI)
1.0
Actual data, no CI needed
52.2% (38.0–66.6)2. Materials and methods
For thismeta-analysis, we reviewed the published literature to iden-
tify country-level studies reporting maternal syphilis seropositivity re-
sults for both treponemal and non-treponemal tests on all patients in
order to estimate the likelihood that a single unconﬁrmed syphilis test
would also be positive for the alternative test type, had it been
conducted.
To identify studies, we conducted a systematic Medline search using
the terms: “Syphilis [Mesh] and Pregnancy [Mesh],” “Syphilis [Mesh]
and Prenatal Diagnosis [Mesh],” and “Syphilis [Mesh] and Antenatal
[Keyword]”, including observational studies (trials, cross-sectional
serosurveys, and cohort and case-control studies) published be-
tween January 2000 and November 2013, and reporting both non-
treponemal and treponemal syphilis testing results of any type in preg-
nant or puerperal women. We also looked at the three studies used in
the original WHO correction factor estimate [3–5].
2.1. Inclusion criteria
To be included, eligible studies must have tested pregnant or puer-
peralwomen for both non-treponemal and treponemal serology and re-
ported at least one of the following: the proportion of pregnant or
puerperal womenwith reactive non-treponemal tests that had reactive
treponemal tests (correction factor for Category 2 countries) or the pro-
portion of pregnant or puerperal womenwith reactive treponemal tests
that had reactive non-treponemal tests (correction factor for Category 3
countries). Studies were included regardless of type of non-treponemal
(e.g. RPR, VDRL) or treponemal (e.g. ﬂuorescent treponemal antibody
absorption, TP-PA) test used, publication language, country, or age of
subjects.
We used these data to estimate maternal syphilis seropositivity for
countries reporting data toWHO based on a single test type (Categories
2 and 3), or that did not report the test type used (Category 4; Table 2).
For Category 1 countries, we assumed that reported data should be used
without correction since these are the best possible estimates for PAS
cases in pregnancy when only test type (no clinical or titer) data are
available. For Category 2 countries, we used the published literature to
calculate estimates and 95% conﬁdence intervals (CIs) for the propor-
tion of pregnant women with reactive non-treponemal tests that also
had reactive treponemal tests (i.e. A/(A+B) fromTable 1). For Category
3 countries, we used the published literature to calculate estimates and
CIs for the proportion of pregnant women with reactive treponemal
tests that also had reactive non-treponemal tests (i.e. A/(A + C) from
Table 1). For Category 4 countries, we assumed an equal probability of
having used only non-treponemal, only treponemal, or a combined
test strategy. Thus, we used the average of the estimates for the
three correction factors for Categories 1 − 3 to estimate the numberpe, assumptions for new correction factors, and new correction factor estimates.
sed on reactive
only)
Category 3
(countries reporting based on
reactive treponemal testing)
Category 4
(countries not reporting type of
testing used)
65% 65%
t women
onemal tests
treponemal
Table 1
Proportion of pregnant womenwith
reactive treponemal tests that also
have reactive non-treponemal tests;
A/(A + C) from Table 1
Non-reporting countries would
be evenly distributed between
Categories 1–3: average of the
correction factors for Categories
1–3
53.6% (36.9–70.2) 68.6% (61.3–78.9)
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factor + Category 3 correction factor)/3). The estimated proportions
for each WHO reporting category represent the correction factors to
be used for their respective categories.
2.2. Statistical analysis
For each study identiﬁed from the literature review, based on the
reported data, we manually retrieved or calculated the crude percent
estimates of subjects with both reactive treponemal and reactive non-
treponemal tests among subjects with reactive treponemal (Category
2) and among subjects with reactive non-treponemal (Category
3) tests and corresponding 95% CIs for the assessed outcomes. We sum-
marized the percent estimates using random effects models, which take
into account the presence of between-study heterogeneity into the cal-
culations. This approachwas chosen over a ﬁxed effectsmodel since the
underlying syphilis prevalence and other factors were different in each
population studied.
3. Results
The MEDLINE search identiﬁed 514 studies along with two of the
three studies identiﬁed in the WHO 2008 estimates literature search
that met our inclusion criteria [1]. Of the 516 studies screened for eligi-
bility, 29 met the criteria and were included in the analyses [3,5–32]
(Fig. 1). Studies could be included in more than one analysis depending
on what type of results were reported: once for estimating the
correction factor for Category 2, once for Category 3, and all were
included in the Category 4 estimate. In total, 24 of the 29 studies reported
A/(A + B) results (Table 1) [3,5–25,33,34], representing 1896 women
used to estimate the correction factor for Category 2 countries; and 13
of the 29 reported A/(A + C) results [3,5,8,9,14,16,18,26–30,33],Records identified through 
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Fig. 1. Flow diagram orepresenting 1132 women included for the estimate for Category 3
countries. The studies were conducted in various clinical settings (e.g.
hospitals, ANC clinics, rural clinics, urban clinics) and represented 22
countries. The study estimates and CIs for Category 2 and 3 countries
are shown in Fig. 2.
Followingpooling of the results from individual studies and account-
ing for within- and between-study variation using the random effects
model, the correction factor for Category 2 countries was estimated to
be 52.2% (95% CI, 38.0–66.6), indicating that an estimated 52.2% of the
syphilis cases in pregnancy reported to WHO by these countries were
likely to have PAS (Table 2). Using the random effectsmodel, the pooled
correction factor for Category 3 countries was quite similar, calculated
as 53.6% (95% CI, 36.9–70.2; Table 2). As previously discussed, Category
1 countries reported the best possible estimates as data were based on
both treponemal and non-treponemal testing results, and thus the cor-
rection factor was set as 1.0. For Category 4 countries, we used the aver-
age of the correction factors calculated for the ﬁrst three categories, and
the correction factor was calculated as 68.6% (95% CI, 61.3–78.9;
Table 2). Thus, an estimated 68.6% of cases in pregnancy reported by
these countries were likely to have been PAS.4. Discussion
This analysis was conducted to improve future estimates of the global
burden of syphilis in pregnancy and the related adverse outcomes. The
meta-analysis results indicate that, among countries reporting maternal
syphilis infections using a single test result, regardless of test type, an es-
timated 53% of cases represent sufﬁciently active infections to result in
transmission of syphilis frommother to fetus. For countries not reporting
test type, approximately 69% of cases are estimated to have sufﬁciently
active infections to result in MTCT. Had the correction factors calculated
herein been used in the 2008 WHO estimates, there would have beenAdditional records identified through 
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Fig. 2.Meta-analysis of studies reporting non-treponemal (NT) and treponemal (TP) test results in pregnant women and correction factor estimates for theWHO reporting Categories 2
and 3with 95% CIs. *Points represent reported study values for given Category; bars represent 95% CIs. EIA, Enzyme immunoassay; FTA-Abs, Fluorescent treponemal antibody absorption;
RPR, Rapid plasma regain; TPHA, T. pallidum hemagglutination assay; TP, Treponema pallidum; VDRL, Venereal disease research laboratory.
S13D.C. Ham et al. / International Journal of Gynecology and Obstetrics 130 (2015) S10–S14an increase in syphilis cases in pregnancy (1 408 811 vs 1 473 152 infec-
tions, or a 4.6% increase), and a proportionately similar increase in associ-
ated outcomes. Nevertheless, despite the difference between using a
uniform or a variable correction factor based on reported test type not
being signiﬁcant in 2008, testing practices within countries may evolve
over time and, thus, this may not always be the case. Furthermore, efforts
are being made byWHO and UNAIDS to improve maternal syphilis sero-
positivity test type reporting, which will allow for improvements in the
accuracy of estimates. Accurate estimates are important to evaluate prog-
ress in global and regional congenital syphilis elimination initiatives as
well as for strategic planning [33].
Serologic testing is inherently imprecise in identifying infectious
syphilis. Positive predictive values of tests vary according to population
prevalence, clinical stage of disease, prior history of disease and treat-
ment, and quality of laboratory testing. In pregnancy, MTCT risk can
be inﬂuenced by co-infection with malaria or HIV [34]. Health systems
with accurate laboratory testing and strong antenatal programs arelikely to better identify true syphilis cases earlier in the course of preg-
nancy, leading to disease prevention. In settings with a stronger public
health infrastructure, unconﬁrmed reactive treponemal tests are likely
to represent previously treated syphilis infections; while in settings
with weak testing and treatment infrastructures, unconﬁrmed reactive
treponemal tests are likely to represent untreated syphilis. A clinical his-
tory can help distinguish previously treated from newly infected cases;
however, these data are not available in WHO (or most national) sur-
veillance systems, and their inclusion in routine surveillance is
impractical.
It must be noted, however, that this study is not without limitations.
First, the studies included in the meta-analysis varied in their setting
(urban vs rural), underlying syphilis and other disease prevalence, and
available health care and laboratory infrastructure. Further, despite hav-
ing estimated the results using a random effects model, the correction
factors are unlikely to be generalizable to every individual locale,
country, or region. In particular, the underlying prevalence of syphilis
S14 D.C. Ham et al. / International Journal of Gynecology and Obstetrics 130 (2015) S10–S14in pregnant women will greatly affect the correction factor in Category
3. Second, relatively few studies in the published literature reported
syphilis seropositivity in pregnancy for both treponemal and non-
treponemal tests. It is hoped that, over time, more study data will be
available to further reﬁne the correction factor estimates. Third,
although a structured search was performed, the possibility of unpub-
lished studies showing different results leads to a likelihood of selection
bias in the studies included in the meta-analysis.
Despite these limitations, our study describes how estimates of ma-
ternal syphilis can be improved by correcting for test type. While not
perfect, the correction factors calculated herein represent a step toward
improved accuracy in estimating the global burden of syphilis infections
in pregnant women and resultant perinatal health outcomes. This up-
dated methodology, along with improvements in global reporting of
test types, development of more sensitive and speciﬁc syphilis tests,
and improved access to syphilis diagnostics in resource-poor settings,
are likely to improve the global estimates of syphilis in pregnancy and
associated outcomes in the future. Although this study focuses on ma-
ternal syphilis, themethodology could be applied to other global disease
estimates where biomarkers are used to measure burden of disease.
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